Verrica PharmaceuticalsVRCA
VRCA
About: Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Employees: 71
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
173% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 11
0.93% less ownership
Funds ownership: 33.05% [Q4 2024] → 32.11% (-0.93%) [Q1 2025]
6% less funds holding
Funds holding: 80 [Q4 2024] → 75 (-5) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
38% less capital invested
Capital invested by funds: $20.9M [Q4 2024] → $13M (-$7.88M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for VRCA.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City.
Neutral
Seeking Alpha
1 month ago
Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2025 Corporate Update Conference Call May 13, 2025 4:30 PM ET Company Participants Kevin Gardner - Managing Director LifeSci Advisors Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Serge Belanger - Needham and Company Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' First Quarter 2025 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.38 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4'24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica's candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceutical – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced financial results for the quarter ended March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m.
Neutral
GlobeNewsWire
1 month ago
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City.
Neutral
GlobeNewsWire
2 months ago
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D.
Positive
Zacks Investment Research
2 months ago
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
GlobeNewsWire
2 months ago
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
Neutral
GlobeNewsWire
2 months ago
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer.
Charts implemented using Lightweight Charts™